^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCL20-L

    i
    Other names: CCL20, C-C Motif Chemokine Ligand 20, LARC, Small Inducible Cytokine Subfamily A (Cys-Cys), Member 20, Liver And Activation-Regulated Chemokine, Macrophage Inflammatory Protein 3 Alpha, Chemokine (C-C Motif) Ligand 20, Small-Inducible Cytokine A20, C-C Motif Chemokine 20, CC Chemokine LARC, MIP-3-Alpha, MIP-3a, SCYA20, MIP3A, CKb4, ST38, Beta Chemokine Exodus-1, Beta-Chemokine Exodus-1, Exodus-1, Exodus
    Entrez ID:
    6364
    Related biomarkers:
    Expression
    6ms
    High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy. (PubMed, Cancers (Basel))
    CCL20 may represent a novel blood-based biomarker for the prediction of resistance to immunotherapy that can be used in combination with established strong clinical predictors (e.g., ECOG performance score) and laboratory markers (e.g., S100) in advanced melanoma patients. Future prospective randomized trials are needed to establish CCL20 as a liquid biopsy-based biomarker in advanced melanoma.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CCL20 (C-C Motif Chemokine Ligand 20)
    |
    CCL20-L
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)